Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.50 |
| ▸ | ESR1 | P03372 | 13/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668880 | 0.95 | CYP19A1 (0.50) | CYP19A1ESR1ESR2CYP1A2CYP3A4 | |
| SCHEMBL3813207 | 0.93 | CYP19A1 (0.57) | CYP19A1ESR1ESR2CYP1A2CYP3A4 | |
| SCHEMBL5048730 | 0.91 | ESR1 (0.49) | CYP19A1ESR1ESR2PRSS1 | |
| SCHEMBL5052671 | 0.89 | ESR1 (0.51) | CYP19A1ESR1ESR2PRSS1 | |
| SCHEMBL14075688 | 0.88 | CYP19A1 (0.49) | CYP19A1ESR1ESR2CYP1A2CYP3A4 | |
| SCHEMBL4665860 | 0.88 | CYP19A1 (0.57) | CYP19A1ESR1ESR2CYP1A2CYP3A4 | |
| SCHEMBL4666434 | 0.84 | ESR1 (0.51) | CYP19A1ESR1ESR2 | |
| SCHEMBL3817125 | 0.83 | ESR1 (0.54) | CYP19A1ESR1ESR2PRSS1 | |
| SCHEMBL5075269 | 0.82 | ESR1 (0.60) | ESR1ESR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14531982 | 0.81 | CYP19A1 (0.46) | CYP19A1ESR1ESR2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951217-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080234199-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-20080234199-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-20080234199-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| EP-1951217-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062148-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234199-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | CYP19A1 7/4885ESR1 3/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.